The novel tool could result in earlier prostate cancer diagnoses and less invasive testing, although a prostate cancer expert cautioned that the model makes multiple assumptions and has not been validated.
Use of the nomogram, along with factors such as PSA level and family history, is a reliable, useful tool for helping urologists and their patients make better treatment decisions, says the author of a recent study.
The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
Urologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.
A new study revealing 91% of very low-risk and 74% of low-risk prostate cancer patients in Sweden choose active surveillance should be a benchmark for the use of the management strategy in the U.S. and elsewhere in the world, the study’s authors say.
Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.